Loading...
Docoh

Kinnate Biopharma (KNTE)

News

From Benzinga Pro
Piper Sandler Maintains Overweight on Kinnate Biopharma, Lowers Price Target to $30
19 May 22
News, Price Target, Analyst Ratings
Piper Sandler analyst Christopher Raymond maintains Kinnate Biopharma (NASDAQ:KNTE) with a Overweight and lowers the price target from $52 to $30.
Kinnate Biopharma Q1 EPS $(0.61) Down From $(0.40) YoY
12 May 22
Earnings, News
Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(0.61) per share. This is a 52.5 percent decrease over losses of $(0.40) per share from the same period last year.
53 Biggest Movers From Yesterday
30 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Kinnate Biopharma FY EPS $(2.06) Up From $(5.28) YoY
28 Mar 22
Earnings, News
Kinnate Biopharma (NASDAQ:KNTE) reported quarterly losses of $(2.06) per share. This is a 60.98 percent increase over losses of $(5.28) per share from the same period last year.
Stocks That Hit 52-Week Lows On Monday
7 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 524 stocks hit new 52-week lows.
Kinnate Biopharma Inc. Presents Data From Its Real-World Clinico-Genomic Study Collaboration With Tempus At The Virtual ESMO Targeted Anticancer Therapies Congress
7 Mar 22
Biotech, News, Events, General
Kinnate Biopharma Inc. (NASDAQ:KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers,
Stocks That Hit 52-Week Lows On Monday
28 Feb 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday morning, 66 companies achieved new lows for the year.